Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Overview Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Companies Involved in Therapeutics Development AbbVie Inc Galaxy Biotech LLC GlaxoSmithKline Plc Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drug Profiles ABBV-621 - Drug Profile Product Description Mechanism Of Action R&D Progress AY-4 - Drug Profile Product Description Mechanism Of Action R&D Progress Biologic to Agonize TRAIL Receptor 1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress CD19L-sTRAIL - Drug Profile Product Description Mechanism Of Action R&D Progress dulanermin - Drug Profile Product Description Mechanism Of Action R&D Progress HuD-114 - Drug Profile Product Description Mechanism Of Action R&D Progress HuYON-007 - Drug Profile Product Description Mechanism Of Action R&D Progress M-921 - Drug Profile Product Description Mechanism Of Action R&D Progress mapatumumab - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Dormant Products Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Discontinued Products Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Product Development Milestones Featured News & Press Releases Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie Jun 09, 2010: Human Genome Sciences Announces Results Of Phase II Trial Of Mapatumumab In Multiple Myeloma Mar 17, 2010: Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Non-Small Cell Lung Cancer Dec 20, 2008: Human Genome Sciences Initiates Second Randomized Phase II Trial Of HGS-ETR1 In Combination With Chemotherapy Sep 02, 2008: Human Genome Sciences Reports Initial Results Of Randomized Phase II Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma Aug 22, 2008: Human Genome Sciences Completes Enrollment In Randomized Phase II Trial Of HGS-ETR1 In Non-Small Cell Lung Cancer Oct 24, 2007: Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trial Receptor Antibodies In Combination With Chemotherapy Jul 20, 2006: Human Genome Sciences Initiates Randomized Phase II Clinical Trial Of HGS-ETR1 In Combination With Bortezomib Dec 13, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma Nov 01, 2005: Human Genome Sciences Reports Results Of Phase 2 Clinical Trial Of HGS-ETR1 In Patients With Advanced Colorectal Cancer Aug 18, 2005: Glaxosmithkline Exercises Option To Human Genome Sciences' Trial Receptor Antibody Jul 05, 2005: Human Genome Sciences Reports Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer Jun 13, 2005: Human Genome Sciences Reports Interim Results Of Phase II Clinical Trial Of HGS-ETR1 In Patients With Advanced Non-Hodgkin's Lymphoma May 17, 2005: Human Genome Sciences Reports Results Of Phase I Clinical Trials Of HGS-ETR2 And HGS-ETR1 In Patients With Advanced Solid Tumors Apr 18, 2005: Human Genome Sciences Reports Results Of Phase 1 Clinical Trial Of HGS-ER1 In Patients With Advanced Solid Tumors Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AbbVie Inc, H1 2017 Pipeline by Galaxy Biotech LLC, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017 List of Figures Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Top 10 Indications, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

AbbVie Inc Galaxy Biotech LLC GlaxoSmithKline Plc